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ABSTRACT
The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially 
identified and studied in the regulation of glycogen synthesis. GSK-3 functions in 
a wide range of cellular processes. Aberrant activity of GSK-3 has been implicated 
in many human pathologies including: bipolar depression, Alzheimer’s disease, 
Parkinson’s disease, cancer, non-insulin-dependent diabetes mellitus (NIDDM) and 
others. In some cases, suppression of GSK-3 activity by phosphorylation by Akt and 
other kinases has been associated with cancer progression. In these cases, GSK-3 
has tumor suppressor functions. In other cases, GSK-3 has been associated with 
tumor progression by stabilizing components of the beta-catenin complex. In these 
situations, GSK-3 has oncogenic properties. While many inhibitors to GSK-3 have been 
developed, their use remains controversial because of the ambiguous role of GSK-3 
in cancer development. In this review, we will focus on the diverse roles that GSK-3 
plays in various human cancers, in particular in solid tumors. Recently, GSK-3 has 
also been implicated in the generation of cancer stem cells in various cell types. We 
will also discuss how this pivotal kinase interacts with multiple signaling pathways 
such as: PI3K/PTEN/Akt/mTORC1, Ras/Raf/MEK/ERK, Wnt/beta-catenin, Hedgehog, 
Notch and others. 
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Multiple Roles of GSK-3 in Cellular Physiology 
and Human Health
GSK-3 is a serine (S) /threonine (T) kinase. GSK-
3 was initially isolated and purified from rat skeletal 
muscle as a kinase that phosphorylated and inactivated 
glycogen synthase (GS), the last enzyme in glycogen 
biosynthesis [1,2]. Thus GSK-3 was identified initially to 
have important roles in metabolism. GSK-3 is believed 
to be an important regulatory enzyme in many diseases 
and disorders such as: cancer and aging (cancer stem cells, 
cellular senescence, control of stem cell pluripotency and 
differentiation), immune disorders, metabolic disorders 
(atherosclerosis, diabetes, and heart disease), neurological 
disorders (Alzheimer’s, amyotrophic lateral sclerosis 
[ALS], bipolar disorder, mood disorders, Parkinson’s, and 
schizophrenia), and other maladies [3-26]. GSK-3 may be 
a key therapeutic target for these and other diseases [11-
26]. 
GSK-3 has been implicated to play roles in cancers 
which are resistant to chemo-, radio-, and targeted therapy 
[7]. Targeting GSK-3 may be a means to overcome the 
resistance of these cancers to certain chemotherapeutic 
drugs, radiation and small molecule inhibitors [8-10]. 
GSK-3alpha and GSK-3beta
The GSK-3 gene family consists of two highly 
conserved kinases GSK-3alpha and GSK-3beta. However, 
the two molecules have distinct roles and one can not 
compensate for the loss of the other. In fact, expression 
of GSK-3alpha did not rescue embryonic lethality in mice 
in which GSK-3beta gene has been disrupted. GSK3A and 
GSK3B encode 51 and 47 kDa proteins respectively [28]. 
The GSK-3alpha isoform has a glycine-rich extension at 
its amino terminus. GSK-3alpha and GSK-3beta display 
98% sequence identity in their kinase domains but only 
36% identity in their carboxyl termini [29]. GSK-3alpha 
and GSK-3beta are considered active in non-stimulated 
cells. Both GSK-3-alpha and GSK-3beta exhibit strong 
preferences for primed substrates; this means they prefer 
substrates which have already been phosphorylated by 
other kinases [(e.g., casein kinase-1 (CK1), mitogen 
activate protein kinases (MAPK) [extracellular regulated 
kinase (ERK), p38MAPK, and c-Jun N-terminal kinase 
(JNK)], 5’ adenosine monophosphate-activated protein 
kinase (AMPK)] and others. The GSK-3 kinases 
phosphorylate greater than 40 proteins including over 12 
transcription factors [30]. Figure 1 presents a diagram 
indicating some of the substrates of GSK-3. 
Differences between GSK-3alpha and GSK-3beta.
GSK-3alpha and GSK-3beta are structurally similar, 
however, they are not functionally identical and they have 
some different substrate specificities. These GSK-3beta 
knock-out mice die around embryonic day 16 due to 
liver degeneration caused by hepatocyte apoptosis [27]. 
Furthermore, GSK-3beta activity was essential for TNF-
Figure 1: Diversity of GSK-3 Substrates. Panel A. 
Transcription factors phosphorylated by GSK-3. Transcription 
factors activated by GSK-3 are indicated in yellow diamond type 
shape with black lettering and P’s in red circles. Transcription 
factors inactivated by GSK-3 are indicated in black diamonds 
with white lettering and P’s in black circles. Panel B. Various 
proteins phosphorylated and activated by GSK-3 are indicated 
in yellow rectangles with black lettering and P’s in red circles. 
Various proteins phosphorylated and inhibited by GSK-3 
are indicated in black rectangles with white lettering and P’s 
in black circles. In some cases, an individual protein may be 
activated or inhibited by GSK-3 phosphorylation. This diagram 
is intended to provide the reader an idea of the diversity of GSK-
3 substrates and the roles of GSK-3 in regulating the activity of 
these substrates.
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alpha-induced NF-kappaB activation in hepatocytes. 
In contrast GSK-3alpha knockout mice are viable but 
exhibited enhanced glucose and insulin sensitivity and 
reduced fat mass. GSK-3alpha knock-out mice elicited 
metabolic and neuronal developmental abnormalities 
[31,32]. GSK-3alpha and GSK-3beta have different 
substrate preferences in the brain [33] and likely other 
tissues. Thus, GSK-3 isoforms exhibit tissue-specific 
physiologically important functions which are may not 
be overlapping and sometimes may be different. These 
and other studies indicate that there are rationales for the 
specific targeting of GSK-3alpha or GSK-3beta in certain 
diseases.
Most biochemical studies have focused on GSK-
3beta; however, some studies have demonstrated roles 
for GSK-3alpha in drug resistance and cancer stem cells. 
GSK-3alpha was recently identified as a key target in 
acute myeloid leukemia (AML) [34]. Thus the generation 
of isoform specific inhibitors could result in more specific 
treatments. 
GSK-3 Activity is Controlled by Phosphorylation/
Dephosphorylation
GSK-3alpha and GSK-3beta are expressed 
ubiquitously and highly conserved. Their activities are 
regulated by diverse stimuli and signaling pathways. 
The activity of GSK-3alpha is extinguished by 
phosphorylation at S21, while GSK-3beta activity is 
silenced by phosphorylation at S9. These phosphorylation 
events at S21 and S9 inhibit GSK-3 activity by inducing 
a pseudosubstrate conformation in the substrate docking 
motifs of GSK-3alpha and GSK-3beta respectively [28-
30]. Phosphorylation of GSK-3beta at S9 leads to its 
inactivation by proteasomal degradation and has been 
associated with many pathological conditions, including 
cancer. Various kinases phosphorylate GSK-beta at S9 
including protein kinase A (PKA), protein kinase B 
(PKB a.k.a Akt), p90 ribosomal S6 kinase (p90Rsk), p70 
ribosomal S6 kinase (p70S6K) [28-30, 35-39]. A diagram 
depicting sites of regulation of GSK-3beta is presented in 
Figure 2. 
Insulin signaling results in activation of Akt and 
subsequent phosphorylation and inactivation of GSK-3beta 
(S9) and GSK-3alpha (S21) [37]. Epidermal growth factor 
(EGF), platelet derived growth factor (PDGF) and other 
growth factors also induce the phosphorylation of GSK-
3beta (S9) and GSK-3alpha (S21) by the activated Raf/
MEK/ERK/p90Rsk1 signaling pathway [39]. Other signaling 
pathways induce the phosphorylation and inactivation of 
GSK-3beta and GSK-3alpha by phosphorylation at S9 and 
S21 respectively [37-42]. Thus GSK-3 activity is often 
shut off after exposure to mitogenic/growth factors.
Elucidation of the crystal structure of GSK-3 has 
helped to reveal how the phosphorylation of GSK-3beta 
and GSK-3alpha at S9 and S21 respectively results in 
their inhibition [29]. When either S9 or S21 of GSK-
3beta or GSK-3alpha respectively, are phosphorylated, a 
primed pseudosubstrate is created which folds and binds 
the positively-charged pocket. This folding prevents the 
phosphorylation of substrates as the catalytic groove is 
blocked. This is a competitive mechanism of inhibition 
and if elevated concentrations of the substrates are 
present, they will out-compete the pseudosubstrate and 
the substrates will be phosphorylated [43]. 
Arginine 96 of GSK-3beta is a critical component 
of the positive pocket which binds primed substrates. 
Mutation of arginine (R) 96 of GSK-3beta to alanine (A) 
(R96A) has consequences on the ability of GSK-3beta to 
phosphorylate primed vs. unprimed substrates. Priming of 
substrates usually occur N+4 from the site where GSK-3 
phosphorylates the substrate [29]. Namely if the substrate 
is primed, which is a preference of the GSK-3s; they will 
not be phosphorylated when R96 is mutated to A, whereas 
if they are not primed they will be phosphorylated. 
The R96A mutation disrupts the GSK-3beta pocket of 
positive charge and prevents the phosphorylation of the 
primed substrates. The R96A mutation prevented the S9-
phosphorylated GSK-3beta pseudosubstrate from folding 
back and resulted in the phosphorylation of unprimed 
substrates even when GSK-3beta was phosphorylated at 
S9 [44]. A peptide of eleven amino acids corresponding to 
Figure 2: Sites of Phosphorylation of GSK-3beta 
which Regulate its Activity. Kinases which phosphorylate 
GSK-3beta which result in its inactivation are indicated by 
yellow ovals with inhibitory black lines. Phosphatases such 
as PP1 and PP2A have been reported to dephosphorylate 
S9 which could activate GSK-3beta are indicated in yellow 
octagons with black arrows. The Y216 site of GSK-3beta has 
been reported to be phosphorylated by Fyn and PYK2; these 
are indicated by green ovals with red arrows. Finally, GSK-
3beta may autophosphorylate itself at Y216, which would lead 
to its activation; this is indicated by a yellow oval with a red 
arrow. This figure is provided to give the reader an idea of the 
complexity of regulation of GSK-3 by various kinases and 
phosphatases.
Oncotarget2884www.impactjournals.com/oncotarget
the phosphorylated amino terminal of GSK-3beta inhibited 
competitively the phosphorylation of both primed and 
unprimed substrates [43]. In contrast, a truncated version 
of this peptide only inhibited phosphorylation of primed 
substrates. These results point to different approaches 
to specifically inhibit the ability of GSK-3beta to 
phosphorylate different substrates.
Phosphorylation of GSK-3beta at tyrosine (Y) 
216 also regulates it activity and may activate GSK-
3beta. This may be due to autophosphorylation [45] 
but it may also be mediated by kinases such as Src. 
Y279 is the corresponding residue present in GSK-
3alpha. Phosphorylation of GSK-3beta at Y216 may be 
constitutive in resting cells [45,46]. Apoptotic stimuli can 
increase Y216 phosphorylation of GSK-3beta indicating 
roles for GSK-3beta in cell death [47-52]. The proline-
rich tyrosine kinase 2 (PYK2) may phosphorylate GSK-
3alpha and GSK-3beta at Y216 and Y270 respectively 
[53]. PYK2 controls lysophosphatidic acid-induced 
activation of GSK-3 which regulates the phosphorylation 
of microtubule-associated proteins. PYK2-mediated 
activation of GSK-3 destabilized microtubules during 
actinomyosin-driven neurite retraction [54,55]. The Fyn 
tyrosine kinase also phosphorylates GSKs [45,56]. The 
MAPK family also regulates the activity of GSK-3s. 
p38MAPK phosphorylates GSK-3beta at S389/T390 
[57]. ERK phosphorylation of GSK-3beta at T43 has been 
proposed to induce a conformational change in GSK-3 
which alters its activity [30]. Finally protein phosphatases 
(e.g., PP2A, PP1) have important roles in regulation of 
GSK-3 activity by removing the phosphate on S9 as well 
as other regulatory residues [58,59]. In addition, GSK-3s 
likely have protein phosphatases as substrates (e.g., PP1G) 
[30].
Biochemical Functions of GSK-3
GSK-3beta represses the expression of certain 
immediate response genes in quiescent cells [60]. GSK-
3 can alter the activity of proteins important in RNA 
translation such as p70S6K [61,62]. The GSK-3-related 
yeast protein Mck1 can inhibit the activity of the major 
mitotic cyclin-Cdk complex Clb2-Cdk1 and regulate 
cellular division [63]. A diagram illustrating some of the 
targets of GSK-3 was presented in Figure 1.
Cell cycle arrest at the G1 phase occurs upon 
inhibition of GSK-3 and subsequent activation of p27Kip-1 
[64]. GSK-3 can also phosphorylate p21Cip1 at T57. This 
phosphorylation event lead to the proteasomal degradation 
of p21Cip1[65]. In contrast, lack of GSK-3-mediated 
phosphorylation of cyclin D1 at T286 and cyclin E at S380 
suppressed their nuclear export and degradation [66-68]. 
GSK-3 has many direct and indirect effects on 
cell proliferation. GSK-3 can regulate the activity of 
transcription factors. Thus it can has important regulatory 
roles on cellular growth [69]. The growth arrest and DNA 
damage 45 (GADD45) and GADD153 genes encode tumor 
suppressors which are checkpoint inhibitors. GSK-3beta 
can regulate the activity of the tumor suppressor TP53, 
which can modulate GADD45 transcription. GADD45 is 
induced by DNA damage and its expression is regulated by 
TP53. The cell cycle is arrested when GADD45 is induced. 
c-Myc can also influence the expression of the GADD43 
and GADD153 genes. GSK-3 can regulate c-Myc activity 
[70]. c-Myc can also modulate the expression of cell 
division cycle 25A (CDC25) gene which encodes an 
important cell cycle regulator gene [69]. 
GSK-3 regulates the activity of other transcription 
factors including NF-kappaB [69,71,72], Snail [73,74], 
Notch [75,76], forkhead [77], CAAT-enhancer binding 
protein (C/EBP) [78]. GSK-3 modifies the activity of 
other transcription factors frequently implicated in cancer 
including: activation protein 1 (AP1) [79] and c-Myc [70]. 
GSK-3beta can phosphorylate NF-kappaB at S468 which 
promoted its proteasomal degradation [80]. GSK-3beta 
also interacted with I-kappaBalpha in epithelial cells [81]. 
Other studies have indicated that GSK-3beta suppressed 
NF-kappaB activity by preventing the degradation of 
IkapaBalpha [82]. Thus GSK-3beta can regulate NF-
kappaB activity by multiple mechanisms.
GSK-3beta also affected TP53 activity [83,84]. 
TP53 and miRNA34 can in turn regulate Snail, which 
is also regulated by GSK-3 [85]. Loss of TP53 activity 
resulted in decreased miRNA34 levels which bound to 
the 3’ends of Snail mRNA and suppressed its expression. 
Hence in the absence of functional TP53, Snail activity 
was increased and epithelial-mesenchymal transition 
(EMT) was promoted. GSK-3 regulated this axis. TP53 
and miRNA34 are normally suppressors of Wnt/beta 
catenin signaling [86].
NF-kappaB and GSK-3 regulate the focal adhesion 
kinase (FAK) [87]. Some extracellular matrix proteins are 
indirect targets of Snail, c-Myc and NF-kappaB [73,74]. 
Certain matrix metalloproteinases are transcriptionally 
regulated by NF-kappaB, C/EBPs and Snail. Furthermore 
Snail represses E-cadherin transcription [83]. GSK-3 
phosphorylates Snail which leads to its nuclear export 
[74,89]. Phosphorylation of Snail by GSK-3 can result 
in the cytoplasmic translocation of Snail and lead to 
increased E-cadherin expression in oral cancer [90]. 
Stabilization of Snail protein, by increased GSK-3beta 
phosphorylation, is also observed during EMT in different 
solid cancer types [91-93]. Snail stabilization and EMT, 
through enhanced Akt activity and subsequent GSK-3β 
phosphorylation, is induced by hepatitis B virus X protein 
(HBx) in HBV-associated hepatocarcinogenesis and in 
hepatocellular carcinoma (HCC) patients which have 
amplification and overexpression of the novel oncogene 
Maelstrom (MAEL) [94,95].
The activity of apoptotic and anti-apoptotic family 
members are also regulated by GSK-3. Bcl-2 expression 
is inhibited by GSK-3beta phosphorylation of CREB 
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[96]. The myeloid cell leukemia sequence 1 (Mcl-1) 
anti-apoptotic factor [97-99] is also regulated by GSK-
3. However, some studies indicate that GSK-3 activity 
may not be required for Mcl-1 degradation [100]. GSK-
3 stabilizes the expression of certain anti-apoptotic Bcl-
2 family members [101-102]. Gsk-3beta can regulate 
BCL2L12a anti-apoptotic signaling. BCL2L12A is an 
anti-apoptotic Bcl-2 family member which is expressed 
at high levels in glioblastoma [103]. When BCL2L12A 
is phosphorylated at S156 by GSK-3beta, it is stabilized 
and has increased anti-apoptotic effects with regards 
to treatment with the drug staurosporin. The effects of 
BCL2L12A expression on apoptosis were inhibited when 
the cells were treated with the GSK-3 inhibitor lithium 
chloride. Interestingly, GSK-3beta and Mcl-1 inactivation 
have been shown to be part of the mechanism of action of 
the anesthetic propofol [104]. 
The expression of the myeloblastosis transcription 
factor (c-Myb) is also regulated by GSK-3beta. c-Myb 
is important in the regulation of BCL2 transcription. 
Suppression of GSK-3beta inhibited the expression of 
c-Myb. c-Myc can form a complex with the lymphoid 
enhancer-binding factor 1 (LEF-1) transcription factor 
and bind the promoter regions of the BCL2 and BIRC5 
(survivin) genes which leads to the prevention of apoptosis 
[105]. 
Pro-apoptotic Bim is also a target of GSK-
3beta. Suppression of GSK-3beta resulted in increased 
expression of Bim in pancreatic cancer cells, but not 
in non-transformed pancreatic epithelial cells. This 
regulation of Bim is thought to occur via JNK-dependent 
mechanisms which involve Bim transcription [106]. 
Bcl-2-associated X protein (Bax) can be 
phosphorylated by GSK-3beta in neuronal cells. 
Bax phosphorylation by GSK-3beta stimulated the 
mitochondrial localization of Bax. This localization of 
Bax had pro-apoptotic consequences [107]. TP53 activity 
in colorectal cancer cells (CRCs) can be in part regulated 
by GSK-3beta. These effects of GSK-3beta on TP53 lead 
to increased levels of Bax [108]. GSK-3 can activate 
the v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog (MAF) transcription factor which enhanced its 
transforming activity [109]. GSK-3 also serves to regulate 
the levels of beta-catenin, a key molecule involved in 
normal development as well as cancer progression [110-
119]. 
Thursday Inhibtition of GSK-3beta activity was 
also shown to be critical for association of two metabolic 
enzymes: hexokinase II [120 PMID: 21430642] and 
muscle isoform of fructose-1,6-bisphosphatase (FBP2) 
[121 PMID: 22154964] with mitochondria which results 
in the protection of the organella against stress stimuli and 
the promotion of ATP synthesis. 
 GSK-3 as a Tumor-Promoter
GSK-3 has various roles in cancer which even after 
years of study remain complex and controversial. GSK-3 
may play positive roles in cell proliferation and its aberrant 
expression as a tumor promoter. GSK-3 is overexpressed 
in various tumor types including; colon, liver, ovarian and 
pancreatic tumors [122-124]. 
Suppression of GSK-3beta expression inhibited 
pancreatic cancer growth and angiogenesis [125]. 
Decreased levels of Bcl-2 and vascular endothelial 
growth factor (VEGF) were detected in cells which 
had GSK-3beta knocked-down. GSK-3 inhibitors may 
be appropriate for treatment of these types of tumors 
exhibiting GSK-3 overexpression in which GSK-3 is 
acting as a tumor promoter.
GSK-3 as a Tumor-Suppressor
GSK-3 also functions as a tumor suppressor. 
GSK-3 can suppress the Wnt/beta-catenin pathway 
by phosphorylating beta-catenin which results in the 
ubiquitin/proteasome-dependent degradation of beta-
catenin. Introduction of kinase-inactive (KI), GSK-3beta 
mutants which presumably functioned as inhibitors of 
the endogenous wild-type (WT) GSK-3beta protein 
stimulated Wnt signaling and mammary tumorigenesis 
[126]. Enforced expression of kinase-dead (KD) GSK-
3beta, which presumably functioned as inhibitors of 
the WT GSK-3beta protein, promoted tumorigenesis 
of breast and skin tumors [127]. Overexpression of 
constitutively-active GSK-3beta mutants, in some 
studies, increased chemosensitivity, cell cycle arrest, 
and reduced tumorigenicity of breast cancers [128-
130]. Pharmacological inhibition of GSK-3 induced 
EMT and invasion in breast cancer [89]. In these studies 
suppression of GSK-3 lead to stabilization of beta-catenin 
which resulted in elevated c-Myc, cyclin-B1 and survivin 
expression and promoted proliferation and tumorigenesis. 
There is perhaps a fine balance with GSK-3 whether it 
functions a tumor suppressor or tumor inducer. 
Expression of KI GSK-3beta in murine mammary 
glands can function as DN mutation and promote breast 
cancer development by stabilizing beta-catenin protein 
expression [126]. The GSK-3beta KI construct stabilized 
beta-catenin expression and increased its nuclear 
localization and upregulated the expression of beta-
catenin target genes such as cyclin D1. The GSK-3beta 
KI gene was driven by a mouse mammary tumor virus 
long terminal repeat (LTR) which contains sequences that 
promoted high level expression of the introduced gene 
in the mammary tissue. Expression of the GSK-3beta 
KI mutant resulted in stabilized beta-catenin expression, 
beta-catenin nuclear localization, activation of a TCF/
LEF-dependent reporter construct and increased cyclin-D 
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mRNA and protein levels. 
Cyclin D1 was detected at high levels in 
approximately 50% of breast cancer patients examined. 
However only 15-20% of these patient samples had 
amplification of cyclin D1 [131-133]. beta-catenin 
transactivation has been associated with cyclin D1 
overexpression in breast cancer [134]. Aberrant GSK-
3beta expression may lead to increased beta-catenin 
transcription which increases cyclin D1 expression. Cyclin 
D1 expression is increased in certain breast cancer patients 
Figure 3: Interactions of GSK-3 with the Ras/PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK Pathways. Some of the 
regulatory interactions between GSK-3 and Ras/PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK pathways are indicated. An activated 
growth factor receptor is indicated in blue. Ras and Rheb are indicated in dark blue ovals. IRS1, Shc, Grb2, Sos and beta-catenin are 
indicated in orange ovals. Kinases are indicated in green ovals with the exception of GSK-3beta which is indicated in a red oval. The p85 
regulatory subunit of PI3K is indicated in a green oval. The phosphatases which inhibit steps in this pathway are indicated in black octagons. 
The phosphatases PP2A and PP1 which may activate GSK-3 are indicated in yellow octagons. NF1, TSC1 and TSC2 are indicated in black 
squares. PIP2 and PIP3 are indicated in yellow ovals. The mTORC1 inhibitor is indicated in a red octagon. The AMPK activator Metformin 
is indicated in a green octagon. mTOR interacting proteins which positively regulate mTOR activity are indicated in yellow ovals. mTOR 
interacting proteins which negatively regulate mTOR activity are indicated in black ovals. Transcription factors activated by either ERK or 
Akt phosphorylation are indicated in yellow diamonds. The FKHR transcription factor that is inactivated by Akt phosphorylation is indicated 
by a black diamond and a white P in a black circle. FKHR is also activated by GSK-3beta phosphorylation which is indicated by a white P 
in a red circle. beta-catenin is indicated in an orange oval. mRNA initiation factors and proteins associated with the ribosome are indicated 
in magenta ovals. mTORC1 phosphorylates the unc-51-like kinase 1 (ULK1) which results in the suppression of autophagy. ULK1 is 
indicated in a black oval. In contrast, AMPK activates both ULK1 and autophagy as well as TSC activity. Proteins involved in the regulation 
of translation are indicated in purple ovals. Red arrows indicate activating events in pathways. Black arrows indicate inactivating events in 
pathway. Activating phosphorylation events are depicted in red circles with Ps with a black outlined circle. Inactivating phosphorylation 
events are depicted in black circles with Ps with a red outlined circle. This figure is provided to give the reader an idea of the complex 
interactions of GSK-3 with various signaling molecules in the Ras/PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK pathways which are 
key in regulating cellular proliferation survival and often become dysregulated in cancer.
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as GSK-3beta regulates cyclin D1 turnover.
Overexpression of the tumor suppressor Axin gene 
in transgenic mice lead to decreased expression of cyclin 
D1 and increased apoptosis in mammary epithelia. In 
addition, impaired lymphoid development was observed 
in these [135]. CK2alpha overexpression in transgenic 
mice resulted in mammary tumorigenesis as under these 
circumstances CK2alpha promoted Wnt signaling [136]. 
We observed that the GSK-3(KD) mutant induced 
doxorubicin resistance in MCF-7 breast cancer cells [137]. 
However, in the same experiments the constitutively-
active A9 GSK-3beta also made the cells slightly 
more doxorubicin resistant than cells transfected with 
the GSK-3beta (WT) construct. Moreover, the GSK-
3beta(KD) construct made the MCF-7 cells more resistant 
to tamofixen than the cells transfected with the GSK-
3beta(WT) construct. However different results were 
observed with rapamycin which blocks mTORC. MCF-7 
cells transfected with the GSK-3beta(KD) construct were 
hypersensitive to rapamycin while cells transfected with 
the constitutively-active GSK-3beta (A9) construct were 
resistant to rapamycin. The cells containing the GSK-
3beta(KD) construct were more sensitive to the GSK-3 
inhibitor lithium than cells harboring GSK-3beta(WT) 
construct.
Mutations in GSK-3 Targets
Since GSK-3 is a kinase with a specific recognition 
motif present in substrate proteins that it phosphorylates, 
mutations can occur in certain genes which prevent 
GSK-3-mediated phosphorylation of the proteins they 
encode. The mutant proteins may have altered half-lifes 
as compared to the WT proteins as they may not be subject 
to proteasomal degradation. For example, mutations 
Figure 4: Wnt/beta-catenin Induced Gene Expression is Modulated by GSK-3. When Wnt is present beta-catenin is stabilized 
and can induce gene transcription. Wnt binds its coreceptors Frizzled (Fz) and LRP5/LRP6. The Fz transmembrane receptor is indicated 
by a squiggly line to indicate its spanning the membrane seven times. The LRP5 and LRP6 transmembrane receptors are indicated by a red 
oval. Various molecules which interact with the receptors and GSK-3 and CK1 are indicated in yellow ovals. In the presence of Wnt, beta-
catenin is stabilized and induces gene expression by complexing with various transcription factors such as TCF/LET, which are indicated 
by yellow diamonds. Various proteins which interact with the transcription factor complexes are indicated in pink circles. 
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changing T58 of c-Myc prevented the ability of GSK-3 to 
phosphorylate c-Myc and thus suppressed its proteasomal 
degradation [138-141]. Genetic mutations changing 
the GSK-3 phosphorylation sites S33, S37, S45 or T41 
present in beta-catenin prevented the ability of GSK-
3beta to phosphorylate beta-catenin and thus inhibited its 
proteasomal degradation. Likewise mutations at S45 of 
beta-catenin prevented CKI from performing the priming 
phosphorylation, thus GSK-3 was unable to phosphorylate 
the other residues of beta-catenin. Thus mutations at GSK-
3 or CKI phosphorylation sites which prevent the ability 
of GSK-3 or CKI to phosphorylate target proteins which 
can under certain circumstances be oncogenic [142-145]. 
The PI3K/PTEN/Akt/mTOR Pathway and GSK-
3. 
The PI3K/PTEN/Akt/mTOR pathway and GSK-
3 can cross-regulate each other at various points. Some 
of the interactions between GSK-3 and the PI3K/PTEN/
Akt/mTOR pathway are presented in Figure 3. As stated 
previously, GSK-3beta is negatively by Akt when it is 
phosphorylated on S9. GSK-3beta is then inactive.
The PI3K/PTEN/mTOR pathway is also involved 
in cancer initiation, metastasis, drug resistance, and 
sensitivity to therapy [146-152]. PI3K p110 catalytic 
subunit (PIK3CA) mutations may be driver mutations in 
certain cancers responsible for metastasis [153]. Novel 
PI3K-alpha inhibitors have been isolated and they inhibit 
metastasis [154]. Most PI3K inhibitors are cytostatic 
rather than cytotoxic and it has been questioned whether 
treatment with a single PI3K inhibitor will be effective 
[155].
The PI3K/PTEN/Akt/mTORC1 pathway 
is important in c-Myc expression in Burkitt’s 
lymphomagenesis in germinal center B cells [156]. The 
PI3K/PTEN/Akt/mTORC1 pathway is also an emerging 
target for mantle cell lymphoma as this cascade is 
upregulated in this cancer [157]. Disruption of PTEN and 
TP53 activity in the thyroid has recently been shown to 
result in murine models of anaplastic thyroid carcinomas. 
This model could be important for the development of 
approaches to target human thyroid carcinomas [158]. 
The PI3K/PTEN/Akt/mTORC1 pathway is a key pathway 
involved in many cancers including gliomas often due 
to aberrant PTEN expression. Recently it has been 
shown that reduction of PIK3CA or PI3K p85 regulatory 
subunit (PIK3RA) cell proliferation impedes proliferation, 
migration, and invasion in glioblastoma multiforme cells 
[159]. In contrast to PIK3CA, PIK3CB (PI3K p110-beta 
catalytic subunit) is oncogenic in its WT configuration 
when it is overexpressed in certain conditions. PIK3CB 
can act like an oncogenic mutant of PIK3CA [160]. 
PIK3CD (PI3K-delta p110 catalytic subunit) 
has been shown to have roles in BCR-ABL-mediated 
chronic lymphocytic leukemia (CLL) by turning off 
breakpoint cluster region (BCR) signaling [162]. Elevated 
PI3K signaling has been detected in certain breast 
cancer subtypes and is believed to drive their abnormal 
proliferation [162]. Novel lipid phosphatases have been 
shown to be important in regulation of this pathway. 
Inositol polyphosphate 4-phosphatase type II (INPP4B), 
is a tumor suppressor gene implicated in many cancers 
including: breast, ovarian and prostate cancers [163]. 
mTORC1 and mTORC2 Complexes
The S/T mTOR kinase is a critical component of 
two complexes, mTORC1 and mTORC2. In the mTORC1 
complex, mTOR complexes with Raptor (Regulatory 
associated protein of mTOR) adaptor protein, DEP domain 
containing mTOR-interacting protein (DEPTOR) and 
mLST8, a member of the Lethal-with-Sec-Thirteen gene 
family, first identified in yeast, FK506 Binding Protein 38 
(FKBP38) and proline-rich Akt substrate 40 kDa protein 
(PRAS40) [150,164,165]. DEPTOR may be a tumor 
suppressor gene as decreased expression of DEPTOR 
results in increased mTORC1 activity [166]. mTORC2 can 
function as the elusive PDK-2 which phosphorylates Akt-1 
on S473 in response to growth factor stimulation [167]. 
LKB1/AMPK Network Interactions with GSK-3 
and PI3K/Akt/mTORC1 Pathway. 
The LKB1/AMP activated protein kinase (LMPK) 
pathway is a key pathway initially investigated in 
metabolic diseases such as diabetes. However, the LMPK 
pathway is now recognized to play important roles in 
cancer and other diseases [165]. The LKB1/AMPK 
pathway can be stimulated by the commonly prescribed 
drugs, such as N,N-dimethylimidodicarbonimidic diamide 
(metformin) and 5-aminoimidazole-4-carboxamide 
1-β-D-ribofuranoside (AICAR). AICAR is used to 
prevent cardiac ischemic injury and is also used in 
diabetes care. Activation of LKB1/AMPK in various 
tumor types results in cell cycle arrest, caspase-dependent 
apoptosis or autophagy in various tumors. Metformin 
inhibits mTORC1-controlled protein translation. Many 
of the targeted proteins are important in the growth of 
malignant cells. The translation of these proteins is not 
as well inhibited with allosteric mTORC1 inhibitors, such 
as rapamycin and its derivatives. Recently it was shown 
that metformin also targets the cancer initiating cells 
(CICs), the critical target for cancer eradication. Thus the 
LKB1/AMPK pathway is critically involved in regulating 
diseases such as diabetes as well as the proliferation and 
survival of malignant cells. Drugs targeting and activating 
LKB1/AMPK maybe a novel, less toxic and cost effective 
treatment option for certain malignancies [168,169]. 
The ability of metformin to suppress the 
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proliferation of T-acute lymphoblastic leukemias (T-ALL) 
cell lines and primary T-ALL patient samples displaying 
mTORC1 activation was examined. Metformin induced 
autophagy and apoptosis and inhibited proliferation. The 
effects of metformin on control CD4+ T-lymphocytes 
were examined. Metformin was much less toxic against 
CD4+ T-lymphocytes from healthy donors than against 
either the T-ALL cell lines or primary patient cells. 
These studies documented the dephosphorylation of 
downstream targets of mTORC1. In addition, inhibition of 
mRNA translation in metformin-treated T-ALL cells was 
observed. In contrast, a similar inhibition of translation 
was not observed after rapamycin treatment. Importantly 
in primary patient samples, metformin targeted the side 
population of T-ALL cell lines as well as a putative 
leukemia initiating cell (LIC) subpopulation (CD34+, 
CD7-, CD4-). Metformin exhibited anti-leukemic 
activity, which supports further development of LKB1/
AMPK pathway activators as potential clinical candidates 
for T-ALL therapy [170]. AMPK is also important in 
BCR-ABL-induced chronic myeloid leukemia (CML) 
and AMPK pathway activators may prove useful as 
combination drug therapy (with BCR-ABL inhibitors) 
for this disease [171]. AMPK can also be activated by 
rapamycin [172]. 
LKB1 is an important tumor suppressor and 
gatekeeper mutations of LKB1 cause the rare Peutz-Jeghers 
Syndrome (PJS) which is a cancer-prone syndrome [173]. 
LKB1 is a critical regulator of cell polarity and energy/
metabolism control and exerts it vast effects via diverse 
effectors [174,175]. AMPK is considered a metabolic 
gatekeeper important in many diseases including diabetes, 
cancer and neurologic disorders. Inhibiting mTORC1 
activity by drugs such as metformin and other drugs 
(including rapamycin) may not only aid in the treatment of 
diabetics, but also improve cancer therapies and increase 
longevity [176-179]. 
The plant natural product berberine has recently 
been shown to inhibit the growth of drug-resistant breast 
cancer cells whereas the parental drug sensitive line was 
not as growth inhibited. Berberine may also target LKB1/
AMPK. Cells overexpressing neutrophil gelatinase-
associated lipocalin (NGAL) were more sensitive to 
berberine than parental cells which did not over express 
NGAL [180]. 
Figure 5: Formation of beta-catenin Destruction Complex. When Wnt is absent, beta-catenin is targeted for proteasomal 
degradation. GMP, indicated in a yellow oval, is displaced from GSK-3 and GSK-3 is able to phosphorylate beta-catenin which results in 
its ubiquitination by the beta-TrCP complex which is indicated in a yellow oval. Ubiquitination is indicated by Ub in purple circles. Axin 
is also poly-ADP-ribosylated (PAR) by tankyrase (TNKS) in a green oval with white letters. PAR is indicated in a purple circle which 
subsequently leads to the proteasomal degradation of Axin. Axin is also ubiquitinated by RNF146 RING-type ubiquitin E3 ligase (RNF146) 
is indicated by a green ovals with white letters.
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Regulation of mTORC by GSK-3, TSC1/TSC2 
and Other Molecules.
The activity of the mTORC1 complex is regulated 
by many different molecules. Akt can suppress tuberous 
sclerosis 2 (TSC2 or tuberin) function by phosphorylation 
[181]. TSC2 is a GTPase activating protein (GAP). TSC2 
functions in association with TSC1 (hamartin) to regulate 
mTORC1 activity. TSC1/TSC2 inactivate the small G 
protein Ras homolog enriched in brain (Rheb) [182]. 
TSC2 phosphorylation by Akt represses GAP activity of 
the TSC1/TSC2 complex, allowing Rheb to accumulate in 
a GTP-bound state. Rheb-GTP then activates the protein 
kinase activity of mTOR present in the mTORC1 complex. 
GSK-3 plays key roles in this regulatory circuit. 
The TSC1/TSC2 complex can negatively-regulate 
proliferation through mTORC1 inhibition and GSK-3beta 
activation. GSK-3 can also interact with TSC1/TSC2 
by phosphorylating TSC2 and activating it [183]. This 
regulatory loop would result in suppression of mTORC1 
activity. 
Akt also phosphorylates the proline-rich Akt 
substrate of 40 kDa (PRAS40), another inhibitor of 
mTORC1. When PRAS40 is phosphorylated by Akt, it can 
not suppress mTORC1 signalling [154,154,165,169,183-
185]. Thus, this is another mechanism by which Akt 
activates mTORC1. To complicate matters, PRAS40 is 
a substrate of mTORC1 itself, and mTORC1-mediated 
phosphorylation of PRAS40 prevents inhibition of 
additional mTORC1 signaling. The Ras/Raf/MEK/ERK 
signaling pathway also regulates mTORC1. TSC2 is 
phosphorylated by both ERK and p90Rsk-1. When TSC2 is 
phosphorylated by either ERK or p90Rsk-1, its inhibitory 
function is suppressed [183-185]. Moreover, inhibition 
of mTORC1 can result in ERK1/2 activation, through 
p70S6K/PI3K/Ras/Raf/MEK [186]. 
The mechanism(s) by which Rheb-GTP activates 
mTORC1 are not fully elucidated. However for Rheb 
to activate mTORC1, Rheb must be farnesylated and 
farnesylation can be suppressed by farnesyl transferase 
(FT) inhibitors. Rheb-GTP may relieve the inhibitory 
function of FK506-binding protein 8 (FKBP38) on mTOR, 
thus leading to mTORC1 activation [182]. 
mTORC1 also inhibits Akt via a negative feedback 
loop which involves p70S6K and potentially other 
molecules [187]. p70S6K can exert negative effects on 
insulin receptor substrate-1 (IRS-1) [154,154,165,169,183-
185]. p70S6K can phosphorylate IRS-1 on S312 and/
or S636/S639. This results in the targeting of IRS-1 
to the proteasome where it is degraded. Hence PI3K/
Akt signaling downstream of IRS-1 is downregulated 
when p70S6K is active. Rapamycin blocks mTORC1 
and p70S6K activation, thus this loop is broken upon 
rapamycin was added and Akt is activated. 
GSK-3 can regulate this pathway by phosphorylation 
of S371 on p70S6K [61,62,65,186,187]. GSK-3 interacts 
with mTORC1 to regulate p70S6K activity [61,62]. GSK-
3beta can have negative effects on p70S6K activity [188]. 
GSK-3 can phosphorylate TSC2 which results in inhibition 
of mTORC1 and prevents the phosphorylation of p70S6K 
at T389 [189,190]. Little is known about the interactions of 
GSK-3 and mTORC2 in oncogenesis. mTORC2 stabilizes 
cyclin D1 through prevention of GSK3- dependent and 
FBX4-mediated cyclin D1 degradation [190] Thursday 
Involvement of GSK-3 in Hematopoietic Stem 
Cell (HSC) Homeostasis
To maintain a balanced number of self-renewing 
cells or to generate the required lineage-differentiated 
progeny cells necessary to fulfill the loss of mature 
blood cells, normal HSCs exit quiescence under the 
appropriate circumstances. GSK-3 plays key roles in HSC 
homeostasis by regulating the quiescent HSC pool [91]. 
Depletion of functional GSK-3 activity in bone marrow 
(BM) transiently expanded HSC in a beta-catenin-
dependent fashion, indicating roles for GSK-3 and Wnt/
beta-catenin signaling in homeostasis. Depletion of GSK-
3 activity in the HSC pool resulted in their depletion by 
activation of mTORC1. Loss of the HSCs in the GSK-
3-deficient BM could be suppressed by treatment with 
mTORC1 inhibitors. GSK-3 is a master regulatory switch 
which controls both Wnt/beta-catenin and mTORC1 
signaling which in turn regulates HSC self renewal 
and lineage commitment respectively. This important 
study has suggested a potential therapeutic approach to 
expand HSCs in vivo by using already approved drugs for 
treatment of other diseases (rapamycin/rapalogs to inhibit 
mTORC1 and lithium to inhibit GSK-3).
As stated previously, GSK-3 phosphorylates TSC2 
which in turn inhibits Rheb and mTORC1 activity. 
The PTEN phosphatase is upstream of GSK-3. PTEN 
negatively regulates Akt activity by de-phosphorylating 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) which 
Akt requires for membrane localization. PTEN and TSC1 
knock-out mice have similar hematopoietic phenotypes. 
Increases in HSC were transiently observed which were 
followed by HSC depetion and lineage commitment 
[192,193]. The authors suggested that there were 
additional tumor suppressors which were induced in 
PTEN-mutant mice indicating the complicated interacting 
genetic factors between PTEN loss and mTOR activation 
[194]. Knock-down of GSK-3alpha and GSK-3beta 
induced a similar HSC phenotype as observed in PTEN-
/- and TSC-1-/- mice as the HSCs initially increased and 
then they were progressively depleted [195]. Thus GSK-
3 plays critical roles in HSC homeostasis and regulating 
the decision between self-renewal and differentiation. 
These pathways often have competing functions in HSC 
self renewal and differentiation. Wnt signaling can induce 
mTORC1 activity by preventing the inhibitory effects that 
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GSK-3 has on mTORC activity. Thus there is a division 
of the canonical Wnt pathway with Wnt or GSK-3 
inducing opposing signal pathways. Wnt and GSK-3 can 
activate potentially opposing processes (HSC renewal vs. 
differentiation). Other factors and molecules may also be 
discovered that may modify the balance and modify HSC 
homeostasis.
Nutrient-sensing pathways interact to regulate 
HSC homeostasis. HSCs reside in the BM in a nutrient 
and oxygen-deprived niche. Both the mTORC1 and 
LKB1 pathways are important nutrient-sensing pathways. 
Dysregulation of these pathways alters HSC homeostasis. 
Increased mTORC1 activity or decreased LKB1 activity 
[193,196-199] stimulates the proliferation of committed 
progenitors and decreases HSCs. Low nutrient availability 
is a critical component which controls HSC homeostasis.
Suppression of this pathway by rapamycin 
combined with activation of Wnt/beta-catenin pathway by 
GSK-3 inhibitors permitted ex vivo maintenance of human 
and mouse HSCs in the absence of exogenous cytokines. 
These studies demonstrated that two drugs (GSK inhibitor 
CHIR99021 and the mTOR blocker rapamycin) increased 
the number of long-term HSC in vivo [200]. Thus GSK-3 
plays roles in HSC homeostasis as a suppressor of Wnt/
beta catenin self-renewal pathway and also as a suppressor 
of the mTORC1 pathway which would normally promote 
lineage commitment and stem-cell depletion. Inhibition 
of GSK-3 activated self renewal while suppression 
of mTORC1 prevented HSC depetion allowing the 
generation of long term HSC (but not the proportion) 
in vivo. This approach may also prove useful for both 
hematopoietic recovery and immune reconstitution in 
umbilical cord blood transplantation.
The promyelocytic leukemia (PML)–peroxisome 
proliferator-activated receptor-delta (PPAR-delta)–
fatty-acid oxidation (FAO) pathway is another pathway 
which is important in HSC maintenance [201]. GSK-3 
regulates this pathway. PPARs are regulated by GSK-
3 phosphorylation [202]. Loss of HSC maintenance can 
occur after suppression of PPAR-delta or inhibition of 
mitochondria FAO. Improved HSC maintenance was 
observed after treatment with PPAR-delta agonists. PML 
regulates PPAR signaling and FAO which have important 
roles in HSC maintenance [201]. The asymmetric division 
of HSCs is controlled by this pathway. Thus the PPAR-
FAO pathway is a metabolic regulatory switch for the 
control of HSC fate. PPARs are important transcription 
factors that regulate nutrient sensing and metabolic 
pathways including FAO and fatty acid transport. These 
studies have important therapeutic implications as small 
Figure 6: GSK-3 can Enhance Wnt/beta-catenin signaling. GSK-3 and CK-1 can phosphorylate and stabilize LRP5/6 which 
promotes beta-catenin signaling. GSK-3 inhibitors could inhibit beta-catenin–mediated gene expression. GSK-3 inhibitors are indicated by 
a black octagon with white lettering.
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molecule PPAR activators and inhibitors have been 
developed and evaluated for the treatment of obesity and 
metabolic disorders [203,204]. 
The PML gene is a tumor suppressor gene originally 
cloned from the break point of the t(15;17) chromosomal 
translocation present in PML. PML has an important 
role in regulating the maintenance of HSCs and LIC 
quiescence. Suppressing the activity of PML eliminated 
certain LICs [205]. PML-deficient CML-LICs became 
exhausted over time and lost their ability to generate 
CML in transplanted mice. PML also acted as a negative 
regulator of mTORC1 in a mouse CML model [206-207]. 
Repressing or balancing mTORC1 activity is important in 
HSC maintenance. Elevated mTORC1 activity adversely 
affected LIC maintenance while the mTORC1 blocker 
rapamycin prevented the exhaustion of Pml–/– LICs. PML 
is targeted for degradation by arsenic trioxide. Arsenic 
trioxide treatment of murine CML models decreased 
PML expression and prevented maintenance of CML-LIC 
quiescence. 
GSK-3 inhibition permitted mouse embryonic stem 
cells (ESC) to maintain pluripotency. ESCs prepared from 
mice lacking GSK-3alpha and GSK-3beta retained some 
markers of pluripotency even when they were cultured 
under differentiation-inducing conditions [208-209]. 
GSK-3 and mTORC1 may also regulate T cell 
memory. Importantly inhibition of GSK-3, mTORC1 or 
both may augment the number and competence of CD8+ 
memory T cells [210-212]. 
Involvement of GSK-3 and Wnt/beta-catenin 
Signaling.
Essentially there are two Wnt signaling pathways, a 
canonical Wnt signaling pathway which is beta-catenin-
dependent and a non-canonical Wnt signaling pathway 
which is beta-catenin-independent. Beta-catenin can 
play multiple roles in cell physiology. Different pools of 
beta-catenin likely exist at various subcellular locations. 
For example one pool of beta-catenin is associated with 
cadherins at the cell-cell junctions while another pool 
of beta-catenin is “free” and localized in the cytosol and 
nucleus where it can play important roles in regulating 
gene expression. “Free” beta-catenin exists at a low level 
and is regulated by rapid turn-over. GSK-3 is critical in 
regulating the turnover of beta-catenin. An overview of 
the interactions between GSK-3 and the Wnt/beta-catenin 
pathway is presented in Figure 5.
The Wnt gene family is comprised of approximately 
nineteen genes in mammals. Wnt genes are found in 
multicellular animals but not in single-cell organisms 
suggesting that the Wnt genes played essential roles in 
the evolution of multicellular organisms [213]. When 
Wnt binds it’s receptor, a conformation change of the 
receptor occurs resulting in the phosphorylation of target 
proteins. Wnt binds a member of the Frizzled (Fz) family 
which is comprised of approximately 10 family members. 
Fz proteins are membrane bound receptors which are 
G-protein coupled receptors (GPCRs). The low density 
lipoprotein receptor (LDR) related proteins 5/6 (LRP5 or 
LRP6) are transmembrane proteins which are co-receptors 
for Wnt. Additional proteins can interact with Wnt to 
transduce various signals, these include receptor tyrosine 
kinases (RTKs), such as receptor-tyrosine-kinase-like 
orphan receptor 1 (ROR1) and ROR2 as well as the RTK-
like proteins [214]. 
The GSK-3 Drosophila homologue is zeste-white 
3, a negative regulator of wingless (Wg) signaling which 
is critical for normal development. Wnt is the vertebrate 
homologue of Wg and the Wnts are responsive for 
embryonic patterning as well as many other processes 
and their dysregulation can result in cancer [215]. Wnt 
signaling is complex as at least 19 different Wnts exist 
in mammals and depending on the cellular context, 
different Wnts can induce or suppress critical aspects of 
proliferation. Activation of the canonical Wnt/beta-catenin 
pathway results in the induction of T cell factor/lymphoid 
enhancer factor-1 (TCF/LEF)-responsive genes. beta-
catenin serves as a transactivator which binds to TCF/
LEFs which are bound to specific gene targets in the DNA. 
GSK-3 normally inhibits this pathway as in the 
absence of Wnt ligands; GSK-3 phosphorylates the amino 
terminals domain of beta-catenin which targets it for 
ubiquitination and proteasomal degradation. However, 
when Wnt ligands are present, GSK-3 is inactivated. The 
disheveled (Dvl) phosphoprotein is required to transduce 
a signal from Wnt that results in the inactivation of GSK-
3beta [216]. As a result, beta-catenin is dephosphorylated 
and accumulates in the cytoplasm and translocates to the 
nucleus where it associates with TCF/LEFs to become a 
transcriptional co-activator [29]. 
Regulation of beta-Catenin Activity by GSK-3 
In the absence of stimulation, CK1 phosphorylates 
beta-catenin at S45 which primes beta-catenin for 
subsequent phosphorylation by GSK-3 at S41, S37 and 
S33 [29,143,217-221]. These phosphorylation events 
target beta-catenin for ubiquitination and proteasomal 
degradation [29]. A blow up of the Wnt/beta-catenin and 
beta catenin destruction complex is presented in Figure 5. 
When Wnt ligand is present, it binds Fz, 
which signals through Dvl to suppress beta-catenin 
phosphorylation. beta-catenin is then able to complex 
with LEF/TCF and induces the transcription of genes. 
When beta-catenin is mutated at certain nucleotides it can 
act as an oncogene, as the beta-catenin proteins can not 
be phosphorylated by GSK-3 or CKI (depending on the 
residue). Other regulatory proteins are also involved in 
controlling the activity of the Wnt/beta-catenin complex. 
In many cases, they may be either oncogenes or tumor 
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suppressor genes. GSK-3-binding protein (GBP), also 
known as, frequently rearranged in advanced T-cell 
lymphomas (FRAT), may regulate the binding of GSK-
3 to Axin. Diversin (Div) is an ankyrin rich protein 
that interacts with both Dvl and Axin to promote Wnt 
signaling. The beta-catenin destruction complex consists 
of: beta-catenin, axin/conductin, adenomatous polyposis 
coli (APC), CK1, GSK-3 and GBP. APC is a tumor-
suppressor gene and an essential component of the beta-
catenin complex which controls cytoplasmic beta-catenin 
levels. Mutations at APC are detected in certain cancers 
such as colo-rectal cancer (CRC). Mutations at APC 
occur early in CRC and result in increased beta-catenin 
levels which lead to the expression of Wnt/beta-catenin 
responsive genes. The Axin and related conductin (Axil) 
proteins contain multiple protein:protein interaction 
domains. The Axin/Axil proteins interact with APC and 
form key components of the beta-catenin destruction 
complex. Axin and APC are both phosphorylated by 
GSK-3. Phosphorylation of Axin by GSK-3 increases it 
stability as well as its ability to bind to beta-catenin [222-
225]. CKI is a priming kinase by phosphorylating Axin, 
Dvl and APC. Once these proteins are phosphorylated by 
CK1, GSK-3 then phosphorylates them. The Div protein 
can recruit CKI to the beta-catenin destruction complex 
[226]. 
GBP plays key important roles in the interactions 
between GSK-3 and other proteins. The binding sites for 
Axin and GBP on GSK-3 are overlapping. When GSK-3 is 
bound to GBP, GSK-3 cannot bind Axin and thus GSK-3 
does not phosphorylate beta-catenin [227,228]. GBP can 
regulate the nuclear export of GSK-3 [229] and control 
Figure 7: Overview of Hedgehog Signaling Pathway. The Hh pathway normally inhibits the membrane spanning PTCH1 GPCR 
receptor which is indicated by a squiggly red line crossing the membrane 14 times. PTCH1 normally inhibits SMO which is indicated by a 
purple squiggly line which crosses the membrane 7 times. SMO is then activated in the primary cilium and serves to inhibit SUFU which 
is indicated by a red octagon. SUFU normally inhibits the GLI1 and GLI2 transcriptions factors which are indicated in blue diamonds. 
The Rab23 GTPase may aid in the nuclear translocation of the transcription factors and is indicated by a purple oval. In contrast, GLI3 
is activated by SUFU and may serve as a transcriptional repressor and is regulated by GSK-3. It is indicated in a black diamond. One of 
the genes that are regulated by GLI signaling is IGF2. Dysregulation of Hh signaling pathway occurs in certain cancers. Resistance to Hh 
pathway inhibitors may result from mutations in the pathways which lead to increased pathway expression and autocrine IGF2 expression. 
This figure is presented to give the reader an idea of the negative regulation of the Hh pathway by various components 
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Table 1: GSK-3 Inhibitors
Inhibition Inhibition
Inhibitor Name GSK-3α GSK-3β Structure  Ref/Clinical Trials 
SB216763 + + [308, 309]
TWS119 + [312]















Phase I/II: LY2090314 works in combination with different chemotherapies in treating participants with metastatic pancreatic 
cancer ClinicalTrials.gov Identifier: NCT01632306 Recruiting
Phase I: LY2090314 in combination with pemetrexed and carboplatin in patients with advanced/metastatic cancer 
ClinicalTrials.gov Identifier: NCT01287520 Completed
Phase 2 study of intravenous LY2090314 in participants with acute leukemia ClinicalTrials.gov Identifier: NCT01214603 
Completed
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the accessibility of nuclear and cytoplasmic substrates to 
GSK-3.
Dvl attaches to the cytoplasmic portion of Fz. Wnt/
Fz then associates with the Wnt-coreceptor LRP5 or 
LRP6. CKI phosphorylates and primes LRP6 on T1479. 
GSK-3beta then plays a positive role in Wnt signaling 
by phosphorylating LRP6 on S1490. These events are 
required for Axin to bind to the complex which results in 
beta-catenin stabilization. beta-catenin can then enter the 
nucleus and effect gene transcription [230-235]. Figure 6 
presents a diagram of the positive effects which CKI and 
GSK-3 exert on Wnt/beta-catenin signaling. Targeting 
GSK-3 may be effective in suppressing the growth of 
certain cancers.
Axin attaches to the cytoplasmic portion of LRP6. 
This complex sequesters beta-catenin away from the beta-
catenin destruction complex and suppresses the ability 
of GSK-3beta to phosphorylate beta-catenin. If Wnt 
signaling is turned on, GSK-3-mediated phosphorylation 
of S33, S37 and T41 on beta-catenin is suppressed and 
beta-catenin is stabilized. 
GSK-3 has two roles in regulation of Wnt/beta-
catenin signaling. Phosphorylation of LRP5/6 stabilizes 
Axin while phosphorylation of beta-catenin targets it for 
proteasomal degradation. As stated previously, there may 
be multiple pools of GSK-3 in cells; one linked with Axin 
and is resistant to phosphorylation by Akt. Another pool of 
GSK-3 is regulated by Akt and when it is phosphorylated 
by Akt it is destabilized and degraded [230]. Introduction 
of constructs encoding activated Akt did not activate beta-
catenin signaling in the examined model system in terms 
of changes in levels of LEF1-dependent transcription 
[231]. Wnt may induce GSK-3 and Axin translocation 
to the plasma membrane. These translocations may be 
dependent upon interactions with Fz and Dvl [232-234]. 
Axin is required for GSK-3 to phosphorylate LRP5/6. Wnt 
signaling induces the association of CKI with LRP5/6. 
This association may also be involved in Wnt-induced 
Axin recruitment [290]. 
CKI phosphorylates beta-catenin on S45 when 
Wnt signaling is extinguished. GSK-3beta can then 
phosphorylate beta-catenin on S33, S37 and T41. The 
Axin/GSK-3/CK1/APC complex induces the degradation 
of beta-catenin. This occurs via ubiquitination by the 
SKP1/cullin1-F-box E3 ligase (beta-TrCP) complex in the 
26S proteasome. The tumor suppressor APC interacts with 
both GSK-3 and beta-catenin. Axin serves as the scaffold 
of the destruction complex. APC binds directly to Axin. 
Axin is phosphorylated by CKI and then GSK-3 [291]. 
The affinity of beta-TrCP for beta-catenin is normally low. 
The Wilms tumor suppressor (WTX) protein increases the 
affinity of beta-TrCP for beta-catenin [237]. A complex 
is formed consisting of and APC, Axin, beta-catenin, 
beta-TrCP and WTX, which promotes beta-catenin 
ubiquitination and subsequent proteasomal degradation.
Axin, Apc and WTX are tumor-suppressor proteins. 
APC increases the activity of GSK-3 [238]. GSK-3 
phosphorylates conserved serines present in the PPPSP 
motif found in many Wnt signaling components such as 
beta-catenin, Axin, and APC. 
GSK-3 and beta-Catenin Signaling and 
Hepatocarcinogenesis
The dysregulation of GSK-3beta phosphorylation 
and inhibition of GSK-3beta activity has been shown to 
be involved in hepatocarcinogenesis [239]. In a recent 
study performed on 80 HCC patients, the expression 
of GSK-3beta protein in HCC tissues was found to be 
significantly lower than that in normal liver tissues and 
pericancerous tissues [240]. In addition, low expression 
of GSK-3beta was correlated significantly with advanced 
clinicopathological characteristics and poor prognosis of 
HCC patients. GSK-3beta expression was also correlated 
with vascular invasion, histological grade, TNM 
classification and therefore could be involved in process 
of HCC metastasis [241]. 
In a different study, it was reported that some HCC 
cells expressed high basal levels of S9-phosphorylated 
GSK-3beta [242]. As a result of the sustained 
phosphorylation of GSK-3beta, beta-catenin was stabilized 
and contributed to hepatic transformation. 
Infection with either HBV or HCV are well 
known risk factors for HCC. HBx is one of the four 
proteins encoded by the HBV genome. Several studies 
have reported its involvement in liver carcinogenesis. 
Expression of HBx in hepatocytes activates the Ras/Raf/
MEK/ERK signaling cascade. Interestingly, cross-talk 
between the Ras/Raf/MEK/ERK and Wnt/beta-catenin 
signaling has been observed in hepatoma cells [243]. 
HBx activates ERK and as consequence it associates 
and primes GSK-3beta for its inactivation. In particular, 
activated ERK phosphorylated GSK-3beta at T43, which 
primers GSK-3beta for its subsequent phosphorylation at 
S9 by p90Rsk, resulting in inactivation of GSK-3beta. In 
turn, inactivation of GSK-3beta promoted beta-catenin 
stabilization and signaling [243]. In other scenarios, ERK 
can collaborate with GSK-3 in the phosphorylation of 
paxillin and regulate cytoskeletal rearrangement [244].
Among the HCV encoded proteins, the core protein 
has been reported to contribute to HCC carcinogenesis. 
Interestingly, HCV core protein increases and stabilizes 
beta-catenin levels in hepatoma cells through inactivation 
of GSK-3beta by phosphorylation at S9. This results in 
stabilization of beta-catenin and enhancement of canonical 
Wnt/beta-catenin signaling activity. Downstream beta-
catenin target genes, such as c-Myc, cyclin D1, WNT1-
inducible-signaling pathway protein 2 (WISP2) and 
connective tissue growth factor (CTGF) are expressed at 
higher levels [245].
GSK-3beta/beta-catenin signaling plays roles in the 
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Sirtuin 2 (SIRT2)-mediated transformation in HCC [246]. 
SIRT2 is a member of sirtuin family, which is upregulated 
in about 50% of HCC patients. Increased SIRT2 
expression is correlated with shorter overall survival 
[246]. The sirtuins have been associated with oxidative 
stress and aging [247]. The authors demonstrated that 
SIRT2 regulated activation of Akt by its deacetylation 
[246]. Subsequently Akt phosphorylated and inactivated 
GSK-3beta. The beta-catenin-signaling cascade is 
enhanced and promoted EMT and cell migration of HCC 
cells. Together these results suggested that GSK-3beta is 
probably a tumor suppressor gene in HCC, and the loss of 
GSK-3beta expression and/or activity may contribute to 
development of HCC. 
However, the roles of GSK-3beta in HCC remain 
controversial and several studies indicate that GSK-3beta 
is a potential therapeutic target for a broad spectrum of 
cancer types [248-253] including HCC [254.255]. 
Inhibition of GSK-3beta activity with the GSK3beta 
inhibitors SB-216763 and AR-A014418 controled cancer 
cell survival and proliferation, in a manner unrelated to 
Wnt/beta-catenin signaling and Akt activation, through 
decreasing telomerase reverse transcriptase (hTERT) 
expression and telomerase activity [256]. GSK-3beta 
inhibitors, lithium and SB-415286, have been also reported 
to overcome the inherent resistance of human hepatoma 
cells towards TRAIL-induced apoptosis. The inhibitors 
exerted their anticancer activity through a complex 
mechanism which involved the promotion of apoptotic 
signals (caspase-8, caspase-3 and TP53 activation) and of 
protective signals (JNK activation) [257]. 
Wnt/GSK-3 Regulation of mTORC1 Pathway.
Wnt signaling can regulate the mTORC1 pathway 
via GSK-3 by a beta-catenin-independent mechanism 
[189]. GSK-3 can phosphorylate TSC2 after it has been 
phosphorylated (priming phosphorylation) by AMPK. This 
would lead to inhibition of mTORC1. In contrast, Wnt 
signaling suppresses GSK-3-mediated phosphorylation of 
TSC2 and the mTORC1 pathway is activated. Inhibition 
of Wnt-mediated activation of mTORC1 by rapamycin 
suppressed Wnt-mediated cellular proliferation. Activation 
of AMPK by metformin suppressed Wnt-mediated cellular 
proliferation [192]. In addition to GSK-3, Dickkopf-
related protein 1 (DKK1), Dvl and Axin also modulate the 
effects Wnt has on regulation of mTORC1 and cellular 
proliferation.
Wnt/GSK-3 Signaling in the Regulation of 
SMAD1.
Mothers against decapentaplegic homolog 1 
(SMAD1) is a mediator of the transforming growth factor-
beta (TGF-beta)/bone morphogenetic protein (BMP) 
superfamily of ligands. Both MAPK and GSK-3 were 
determined to phosphorylate SMAD1 on its linker region 
which resulted in its polyubiquitinylation and transport to 
the centrosome where it was degraded by proteasomes. 
The priming phosphorylation mediated by MAPKs (ERK, 
JNK, p38MAPK) to phosphorylate SMAD1 was most 
likely required for GSK-3 activity [258]. Wnt signaling 
decreased GSK-3 phosphorylation of SMAD1. Thus, the 
Wnt/GSK3/SMAD1 pathway plays an important role in 
embryonic pattern formation.
Overview of Hedgehog Pathway.
The hedgehog (Hh) pathway is an important 
developmental pathway that controls segmental pattern 
formation. There are three Hh genes, desert hedgehog 
(DHH), Indian hedgehog (IHH) and sonic hedgehog 
(SHH). These hedgehogs function as ligands for the 12-
pass transmembrane receptor patched (PTCH1) which 
controls many developmental signaling events [259]. Hhs 
can function in some cases as mitogens, while in other 
cases they promote differentiation. An overview of the Hh 
pathway is presented in Figure 7. 
Hh ligands bind their receptor PTCH1. This 
causes its internalization and degradation and release 
of Smoothened (SMO), a GPCR. SMO then promotes 
the dissociation of a suppressor of fused (SUFU)-
glioma-associated oncogene homologue (GLI) complex. 
This allows the transcription factors GLI1 and GLI2 
to translocate to the nucleus and ultimately induce 
the transcription of certain genes. In contrast, GLI3 is 
degraded during this process as it normally functions as 
a repressor. 
GLI3 can be phosphorylated by PKA, GSK-3 and 
CK1 which results in GLI3 becoming a transcriptional 
repressor. Activated GLI proteins stimulate the 
transcription of Hh target genes, including: GLI1, GLI2, 
PTCH1, CCND1, IGF2, MYC, and BCL2. IGF-2 has 
been determined in some studies to subsequently induce 
the PI3K/PTEN/Akt/mTOR pathway and influence 
proliferation and survival as well as inhibit GSK-3beta 
[260]. 
The Hh pathway interacts with other signaling 
pathway regulators such as BMPs, parthyroid hormone 
and retinoids. The Hh pathway is aberrantly regulated in 
certain tumors. There is substantial interest in isolating 
inhibitors which can suppress its activity in various 
cancers and other disorders. 
GSK-3 Regulation of Hh Signaling.
The Hh pathway is regulated by GSK-3 [261]. 
The Hh pathway is inhibited when GSK-3 is suppressed. 
GSK-3beta is a specific binding partner of SUFU, a 
negative regulator of the Hh pathway. SUFU suppresses 
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GLI activity by sequestering GLI in the cytoplasm [262]. 
When GSK-3 phosphorylates SUFU, Hh pathway activity 
is increased. Hh pathway activation stimulates GSK-3beta 
to phosphorylate SUFU which induces the dissociation 
of SUFU from GLI3. GSK-3beta regulates the Hh 
pathway by phosphorylating GLI [263]. The Hh pathway 
activates the GLI transcription factor by suppressing 
the function of SUFU. SUFU recruits GSK-3beta into a 
trimolecular complex of GLI3/SUFU/GSK-3beta. GSK-
3beta then phosphorylates GLI3 which results in a SUFU/
GLI3 transcriptional repressor. Shh then dissociates the 
GLI3/SUFU/GSK-3 beta complex from GLI3 which 
prevents GLI3 processing and results in GLI3 becoming 
a transcriptional activator instead of a transcriptional 
repressor.
Overview of Notch Signaling Pathway.
Notch signaling is important in many processes 
including cellular fate decisions [264]. Notch signaling is 
activated by cell to cell interactions which result in the step 
wise cleavage of Notch first by a TACE- metalloprotease, 
and then a gamma-secretase [265-267]. This cleavage 
results in the release of the Notch intracellular domain 
(NICD). NICD can then translocate into the nucleus to 
bind transcription factors such as centromere binding 
factor (CBF1) which further recruits transcriptional co-
activators including MAML1, histone acetyl transferases 
and cAMP response element-binding protein (CREB)-
binding protein/p300 [268,269]. 
GSK-3 and Notch Signaling Pathway
Notch signaling pathway is regulated by 
GSK-3. GSK-3beta phosphorylates the NICD. This 
phosphorylation event up-regulates NICD transcriptional 
activity by preventing its proteasomal degradation [75]. 
In contrast to the effects of GSK-3, Akt negatively 
regulates NICD activity [270]. GSK-3beta phosphorylates 
domains in the NICD of Notch1 (S/T-P-S/T) which are 
important for the nuclear localization of NICD [271]. 
Phosphorylation of these domains by GSK-3beta 
increased the transcriptional activity of NICD. In contrast, 
other studies have shown that GSK-3 phosphorylation 
can decrease Notch1 protein levels and its transcriptional 
activity [272]. beta-catenin could also modulate the 
transcriptional activity of Notch1/NICD [273]. Beta-
catenin levels are usually increased when GSK-3 is 
suppressed. Other studies have indicated that GSK-3beta 
phosphorylation of Notch downregulates Notch activity 
[274]. Some of these differences in the effects of GSK-3 
on the phosphorylation of Notch observed in the different 
studies may be related to the different cell lines utilized 
or culture conditions. Different culture conditions or cell 
lines containing different mutated activated oncogenes 
activated and tumor suppressor genes inactivatedmay 
affect Notch activity. These studies and others indicate 
the complex interactions between the GSK-3, Wnt/beta-
catenin and Notch signaling pathways.
GSK-3 Inhibitors
One of the first described inhibitors of GSK-3 is 
lithium [275]. Lithium carbonate has been used to treat 
mania patients since 1871. It was approved by the FDA in 
1970 and it is currently used to treat many different types 
of patients with depressive disorders [276]. Early clinical 
studies indicated that lithium had effects on HSCs and 
other hematopoietic cells [277-279]. Lithium increased 
circulating HSCs and peripheral blood counts [280]. 
In 1996, it was proposed that lithium could mobilize 
HSCs for BM transplantations [281]. An important 
consequence of suppression of GSK-3 is stimulation of 
both the Wnt/beta-catenin and PI3K/PTEN/Akt/mTORC1 
pathways. However, GSK-3 has many biological effects 
[275,282,289-299]. 
More than 50 GSK-3 inhibitors have been described 
including: lithium [300], AR-A014418 (beta, IC
50 
=104 
nM) [301], AZD1080 (alpha & beta, orally active, brain 
permeable, with Kis of 6.9 nM and 31 nM respectively) 
[302], AZD2858 (alpha & beta IC
50
s of 68 nM) [303], BIO 
(alpha & beta IC50 of 5 nM) [304], CHIR-99021 (alpha & 
beta, IC
50
s of 10 nM/6.7 nM) [305], CHIR-98014 (alpha & 
beta, IC
50
 of 0.65) [306], LY2090314 (alpha & beta, IC
50
s 
of 1.5 nM and 0.9 nM respectively) [307], SB-216763 
(alpha & beta, IC
50
s of 34.3 nM) [308, 309], SB-415286 
(alpha & beta IC
50
s of 78 nM and 31 nM respectively) 
[310, 311], TDZD-8 (beta, IC
50
 of 2 microM [312] and 
TWS119 (beta, IC
50
s of 30 nM) [313]. Most GSK-3 
inhibitors are ATP-competitive and do not differentiate 
between either GSK-3alpha or GSK-3beta [28]. Tideglusib 
(NP031112) is an irreversible, non ATP-competitive GSK-
3beta inhibitor with IC
50
 of 60 nM, which is in clinical 
trials [284, 314]. Table 1 present a listing of some GSK-3 
inhibitors and their structures and references. 
Clinical Trials with GSK-3 Inhibitors.
Lithium carbonate has been in clinical trials with 
bipolar disorder patients [300]. It is also involved in 
additional clinical trials for patients with Alzheimer 
disease (NCT01055392 & NCT00088387), bipolar 
disorder (NCT01543724, NCT00870311), spinocerebellar 
ataxia type 3 (NCT01096082) and Machado Joseph 
disease. Tideglusib has been in clinical trials for patients 
with Alzheimer’s disease (NCT00948259) and progressive 
supranuclear palsy (NCT01049399). Divalproex 
(Valproate semisodium) is used for treatment of patients 
suffering from bipolar disorder, epilepsy and migraines. 
Divalproex has been in clinical trials in combination 
Oncotarget2898www.impactjournals.com/oncotarget
with lithium, for patients with Alzheimer’s disease 
(NCT00088387), Valproic acid (VPA) is an anticonvulsant 
and mood-stabilizing drug which can inhibit GSK-3beta. 
It has been examined in clinical trials (NCT01548066) to 
determine whether it will prevent hair loss. It has also been 
examined in a clinical trial (NCT00385710) to determine 
if it can aid patients with progressive supranuclear palsy. 
LY2090314 has been in clinical trials for metastatic 
pancreatic cancer [NCT01632306], advanced or metastatic 
cancer in combination with pemetrexed and carboplatin 
[NCT01287520] and acute leukemia [NCT01214603].
GSK-3 Inhibitors in Pre-Clinical Anti-Cancer 
Studies
GSK-3 inhibitors may eventually be used in the 
treatment of certain cancers. GSK-3 is believed to exert 
pro-proliferative effects in solid cancers including: CRC, 
glioblastoma, pancreatic cancer and ovarian cancer and 
in blood cancers including MM, ALL, AML and CLL. 
Therefore it may be appropriate to treat these cancers and 
potentially others with GSK-3 inhibitors [124,284-288]. 
Treatment of the KG1a, K562 and CMK leukemia cell 
lines with the GSK-3 inhibitor SB-415286 resulted in 
GSK-3beta S9 phosphorylation beta-catenin stabilization, 
cyclin B downregulation, cell growth inhibition, cell cycle 
arrest at G
2
/M and apoptosis [289]. Blocking the death 
receptor pathway with an inhibitor of caspase 8 did not 
neutralize the effects of the GSK-3 inhibitor. The GSK-3 
inhibitor treatment resulted in dephosphorylation of Bcl-
2, downregulation of Bcl-XL and led to the depolarization 
of the mitochondrial membrane potential. The role of 
stabilized beta-catenin induced by the treatment of the 
leukemia cells with the GSK-3 inhibitor in the induction 
of apoptosis of these cells is not clear. The GSK-3 
inhibitors SB-415286 and lithium as well as arsenic 
trioxide inactivated GSK-3beta in AML (APL) cells by 
inducing the phosphorylation of S9 on GSK-3beta [290]. 
However, in other cancer types such as breast cancer 
and medulloblastoma, increased GSK-3 expression is 
associated with the induction of apoptosis [291,292]. It 
remains controversial as to whether suppressing GSK-
3 activity with small molecule inhibitors will inhibit or 
promote cancer growth.
1i is a selective ATP competitive inhibitor of GSK-
3. 6-bromoindirubin-3-oxime (BIO) and TWS119 are also 
GSK-3 inhibitors. BIO inhibited GSK-3 and activated 
Wnt/beta catenin signaling, thereby maintaining the 
pluripotency of human and mouse ESCs [208]. Continued 
GSK-3 inhibition or Wnt pathway activation promoted 
ESC differentiation into multipotent mesendodermal 
progenitors or their differential progenitors [293-295]. 
As stated previously, GSK-3 interacts with the Wnt, Hh 
and Notch pathways. These interactions can under the 
appropriate conditions regulate cell fate determination and 
maintenance of stem cells. GSK-3 can phosphorylate the 
GLI2 transcription factor, which can effect differentiation 
[296]. The self-renewal of ESCs was enhanced when 
they were cultured with leukemia inhibitory factor (LIF) 
and BMP3 and GSK-3 were suppressed. The mechanism 
responsible for the enhanced self-renewal is not clear. It 
was proposed that the expression of pluripotency factors 
such as Oct-4 and Nanog was prevented in these conditions 
[295]. GSK-3 may phosphorylate and inactivate other 
transcription factors associated with pluripotency, such as 
c-Myc and c-Jun. 48 derivatives of the GSK-3 inhibitor 1i 
were synthesized by Bone and colleagues. The abilities of 
these GSK-3 inhibitors to maintain undifferentiated ESCs 
were determined. The effectiveness of these compounds 
on maintaining undifferentiated ESCs was linked with 
inhibition of GSK-3 [297]. Thus GSK-3 inhibitors may 
be used to both maintain stem cell pluripotency as well 
as to expand these cells. These inhibitors may also be 
effective with induced pluripotent stem cell generation 
(iPSC) [295]. 
GSK-3 inhibitors may be appropriate for the 
treatment of certain diseases including: diabetes, obesity, 
ischemia, cancer, sepsis, colitis and neurological disorders. 
However, the evaluation of GSK-3 inhibitors in clinical 
trials has been hampered by the fear that inhibition of 
GSK-3 may stimulate or aid in malignant transformation 
as GSK-3 can phosphorylate such pro-oncogenic factors 
as beta-catenin, c-Jun and c-Myc which targets them 
for degradation [28]. However, no studies have been 
reported suggesting that treatment of mice with GSK-3 
inhibitors resulted in an increase in cancer incidence. In 
contrast, studies in prostate, pancreatic, ovarian, thyroid, 
melanoma, brain, pheochromocytoma, paraganglioma, 
colorectal, and hematopoietic cancers have indicated 
that GSK-3 inhibitors could suppress proliferation [298]. 
In fact, many patients with bi-polar disorder have been 
treated with lithium for prolonged periods of time. There 
does not appear to be any evidence that these patients have 
increased incidences of cancer. In the studies by Wang et 
al, treatment on mice with mixed-lineage leukemia (MLL) 
like leukemia (see below) with lithium actually increased 
the survival of the mice approximately 50%.
Treatment of human leukemias containing MLL 
translocations with GSK-3 inhibitors GSK-3 IX, 
SB216763, and allsterpaullone inhibited their growth of 
[64]. GSK-3beta activity was determined to be essential 
for the maintenance of MLL LSC. However GSK-3beta 
activity was not necessary for normal myeloid progenitors 
or progenitors transfected with other non-MLL fusions. 
GSK-3alpha and GSK-3beta performed similar functions 
in regulating the growth of MLL-transformed leukemias. 
p27Kip-1 was critical for the effectiveness of the GSK-
3 inhibitors. Knock-down of p27Kip-1 prevented the 
growth arrest of the GSK-3 inhibitors specifically in 
MLL-transformed cells but not non-MLL fusion protein-
transformed cells. GSK-3 is believed to support the 
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maintenance of MLL-transformed leukemic cells by 
promoting p27Kip-1 degradation. Upon treatment of the 
MLL-transformed cells with GSK-3 inhibitors, p27Kip-1 
accumulated specifically in the MLL-transformed cells and 
cell cycle arrest occurred. 
Effects of Certain Small Molecule Inhibitors on 
GSK-3 Activity
Certain small molecule inhibitors synergized with 
GSK-3beta inhibition to result in cell death [299]. The 
multi-kinase inhibitor sorafenib induced GSK-3beta 
which actually provides a survival signal in melanoma 
cells. When a constitutively-active form of GSK3B was 
introduced into the melanoma cells, elevated levels of anti-
apoptotic Bcl-2, Bcl-XL and survivin were detected while 
decreased levels of pro-apoptotic Noxa were observed. 
Elimination of GSK-3beta activity increased the activity 
of sorafenib.
Summary
Many different biological processes are regulated 
by GSK-3 alpha and beta. GSK-3 interacts with many 
signaling pathways. Critical pathways often dysregulated 
in cancer are the PI3K/PTEN/Akt/mTORC1 and Wnt/
beta-catenin pathways. GSK-3 interacts with both Akt, 
TSC2 to regulate mTORC1. Akt has a negative effect 
on GSK-3 as when GSK-3 is phosphorylated by Akt, 
GSK-3 can not phosphorylate TSC2. This has a pro-
proliferative effect as mTORC1 is not suppressed by 
TSC2. GSK-3 has a negative effect on mTORC as it 
phosphorylates and promotes the activity of TSC2 which 
inhibits mTORC1. This has an anti-proliferative effect. 
mTORC1 and GSK-3 also interact to regulate p70S6K 
which can indirectly regulate Akt. GSK-3 interacts with 
the Wnt/beta-catenin pathway at multiple levels; in some 
circumstances it inhibits the activity of Wnt/beta-catenin 
pathway by phosphorylation of beta-catanin which results 
in its proteasomal degradation, while in other cases it 
promotes the pathway by phosphorylating LRP5/6 which 
results in the stabilization of beta-catenin. This latter 
effect is especially prominent in certain CIC, where GSK-
3 inhibitors may prove clinically effective; however, 
they probably will have to be administered with beta-
catenin or downstream TCF/LEF inhibitors. GSK-3 also 
interacts with the Raf/MEK/ERK, Hh, Notch, and other 
important regulatory pathways. It is intriguing to consider 
why inhibiting GSK-3 does not have dire consequences 
as so many pathways will be affected which will lead to 
activation/suppression of various signaling pathways. 
However, the GSK-3 inhibitor lithium has been used 
to treat patients for many years now without apparent 
increases in the cancer incidence. GSK-3 is a kinase with 
many biochemical, biological and neurological effects. 
Understanding of these effects may lead to improved 
therapies for certain diseases and conditions.
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